Integra LifeSciences Raises Full-Year EPS Outlook, Citi Lifts PT to $16
IART sits 89% above its 52-week low of $8.7.
Summary
Integra LifeSciences has raised its full-year 2026 adjusted EPS outlook to $2.40–$2.50. This positive revision follows the company's Q1 2026 results, which reported adjusted EPS of $0.54 and revenue of $391.9 million, as previously disclosed on May 5th. The increased guidance signals improved future performance expectations from management. In response, Citigroup has raised its price target for IART to $16 from $11 and upgraded its rating to Neutral.
At the time of this announcement, IART was trading at $16.46 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.3B. The 52-week trading range was $8.70 to $16.62. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Wiseek News.